JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

Prognostic model development using novel genetic signature associated with adenosine metabolism and immune status for patients with hepatocellular carcinoma

  • 0National Clinical Research Center for Digestive Diseases and Xijing Hospital of Digestive Diseases, Xijing Hospital, Air Force Medical University, Xi'an, China.
Journal of Physiology and Biochemistry +

|

November 15, 2024

|

November 15, 2024

View abstract on PubMed

Summary

This summary is machine-generated.

This study introduces a new prognostic model for hepatocellular carcinoma (HCC) using adenosine metabolism genes. The model predicts patient survival and reveals links between metabolism, immune response, and HCC progression.

Area Of Science

  • Oncology
  • Molecular Biology
  • Bioinformatics

Background

  • Hepatocellular carcinoma (HCC) has a high mortality rate, often diagnosed at advanced stages.
  • Effective prognostic tools are crucial for improving HCC treatment outcomes.
  • Adenosine metabolism plays a role in cancer development and progression.

Purpose Of The Study

  • To develop a novel prognostic model for HCC based on adenosine metabolizing genes.
  • To investigate the relationship between adenosine metabolism and HCC prognosis.
  • To identify key adenosine metabolism-related genes for predicting HCC patient survival.

Main Methods

  • Utilized RNA sequencing data from public databases to identify differentially expressed adenosine metabolism genes in HCC.
  • Developed an Adenosine metabolism-related risk score (AMrisk) using LASSO Cox regression.
  • Validated the AMrisk model in an independent database and assessed immune cell infiltration and immune checkpoints.
  • Confirmed gene expression levels through quantitative reverse transcription polymerase chain reaction (qRT-PCR) and in vitro experiments.

Main Results

  • Identified 30 differentially expressed adenosine metabolism-related genes in HCC.
  • Developed a six-gene signature (ADA, P2RY4, P2RY6, RPIA, SLC6A3, VEGFA) to calculate the AMrisk score.
  • Demonstrated that higher AMrisk scores correlate with lower overall survival in HCC patients.
  • Observed significantly higher immune infiltration and immune checkpoint activation in the high-risk group.

Conclusions

  • The novel AMrisk model effectively predicts prognosis in hepatocellular carcinoma patients.
  • Adenosine metabolism-related genes are significantly associated with HCC progression and patient survival.
  • The findings suggest a link between adenosine metabolism, immune microenvironment, and HCC outcomes, offering potential therapeutic targets.

Keywords: